Meta AnalysisID 6617
紫龙金片辅助化疗治疗非小细胞肺癌：Meta分析与系统评价
CRD42020197499
To evaluate the therapeutic effects of Zilongjin tablet (ZLJT) combined with chemotherapy in non-small cell lung cancer (NSCLC).
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6617
- Evidence Id
- 15175
- Core Evidence Id
- 15175
- Source Meta Analysis Id
- 6597
- Herb2 Meta Analysis Id
- HBMA006597
- Crd Id
- CRD42020197499
- Title
- Zilongjin tablet adjunct with chemotherapy for the treatment of non-small cell lung cancer: A meta-analysis and systematic review
- Review Question
- To evaluate the therapeutic effects of Zilongjin tablet (ZLJT) combined with chemotherapy in non-small cell lung cancer (NSCLC).
- Study Type Included
- RCTs
- Condition Being Studied
- Lung cancer is the foremost cause of cancer-related deaths globally, of which approximately 80% are non-small cell lung cancer (NSCLC) . NSCLC is one of the lung cancers with devastating and refractory features. The five-year survival rate for NSCLC is barely less than 18% . Most patients with NSCLC have passed the opportunity for radical surgery at the time of diagnosis . For unresectable, patients usually receive treatments including targeted therapy, chemotherapy, radiotherapy, and other palliative care. Platinum-based chemotherapy, a possible treatment for unresectable NSCLC patients, is currently the main nonsurgical treatment because of its efficacy at diminishing tumor size. Although patients can benefit from chemotherapy, the adverse reactions and immunosuppression impact quality of life, which may lead to discontinuation of treatment. Thus, developing new approaches that can minimize adverse reactions and enhance clinical efficacy remains urgent.
- Participant
- Randomized patients with non-small cell lung cancer confirmed by histopathology or cytology
- Animal
- Human Disease Modelled
- Intervention
- Zilongjin tablet combined with chemotherapy
- Comparator Control
- Chemotherapy alone
- Main Outcome
- Objective response rate (ORR), Disease control rate (DCR), Karnofsky Performance Status (KPS), CD3+ T cells, CD4+ T cells, CD4+/CD8+ T cells ratio, natural killer (NK) cells, leukocyte toxicity, platelet toxicity, hemoglobin toxicity, erythrocyte toxicity, gastrointestinal adverse reactions.The primary indicators included ORR, DCR, and KPS. The ORR and DCR were evaluated under the Response Evaluation Criteria in Solid Tumors (RECIST) developed by the World Health Organization (WHO). Responses were categorized as complete remission (CR), partial remission (PR), stable disease (SD), and progressive disease (PD). ORR and DCR were calculated as follows: CR + PR and CR + PR + SD, respectively. KPS was designed to investigate the patient’s quality of life (QOL). QOL was considered stable in more than 10 points of KPS score increment. The secondary outcomes were the alterations in immune function (CD3+ T cells, CD4+ T cells, CD4+/CD8+ T cells ratio, NK cells), and the incidence of grade 3/4 adverse events including gastrointestinal reactions and the reduction of leukocyte, erythrocyte, platelet, and hemoglobin counts, which was evaluated by the WHO Recommendations for Grading of Acute and Subacute Toxicity. Measures of effect The primary indicators included ORR, DCR, and KPS. The ORR and DCR were evaluated under the Response Evaluation Criteria in Solid Tumors (RECIST) developed by the World Health Organization (WHO). Responses were categorized as complete remission (CR), partial remission (PR), stable disease (SD), and progressive disease (PD). ORR and DCR were calculated as follows: CR + PR and CR + PR + SD, respectively. KPS was designed to investigate the patient’s quality of life (QOL). QOL was considered stable in more than 10 points of KPS score increment.
- Outcome Measure
- Additional Outcome
- None Measures of effect None
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Carcinoma, Non-Small-Cell Lung; Drugs, Chinese Herbal; Humans; Lung Neoplasms; Tablets; zilongjin
- Contact
- Li Zhang [email protected]
- Organisational Affiliation
- Affiliated Hospital of Nanjing University of Chinese Medicine
- Funding Source
- This project was supported by the Project of Key Discipline for Traditional Chinese Medicine Construction of Jiangsu Province, China (No. JS1302).
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2020-07-07
- Registration Date
- 2020-08-07
- Anticipated Start Date
- 2020-01-01
- Anticipated Completion Date
- 2020-08-07
- Title Cn
- 紫龙金片辅助化疗治疗非小细胞肺癌：Meta分析与系统评价
- Title En
- Zilongjin tablet adjunct with chemotherapy for the treatment of non-small cell lung cancer: A meta-analysis and systematic review
- Bilingual Status
- complete